Cerenis Therapeutics

Pipeline

Cerenis has built up a portfolio of innovative products that are in different stages of development. These products are based on the reverse lipid transport (RLT) pathway which facilitates the elimination of cholesterol. These products in development are designed to treat cardiovascular disease and related metabolic diseases such as Non-Alcoholic SteatoHepatitis (NASH).
header Products due to enter a new development phase CER-001 Products in the portfolio CER-209 CER-001 (FH) CER-522 CER-002